BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 10897122)

  • 1. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
    Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
    Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
    Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
    Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
    Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
    Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia.
    Stockschläder M; Hegewisch-Becker S; Krüger W; tom Dieck A; Mross K; Hoffknecht M; Berger C; Kohlschütter B; Martin H; Peters S
    Bone Marrow Transplant; 1995 Nov; 16(5):663-7. PubMed ID: 8547863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia.
    Martin H; Atta J; Zumpe P; Eder M; Elsner S; Rode C; Wassmann B; Bruecher J; Hoelzer D
    Exp Hematol; 1995 Dec; 23(14):1612-8. PubMed ID: 8542955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.